Lucy Coutts
Lucy Coutts is an investment director at JM Finn and a shareholder in AstraZeneca. She has expressed skepticism regarding the potential merger between AstraZeneca and Bristol Myers Squibb, suggesting that the only notable advantage for AstraZeneca would be to enhance its U.S. market presence, while indicating that such a deal would likely be more beneficial for Bristol Myers shareholders.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Lucy Coutts commented on the potential merger between AstraZeneca and Bristol Myers Squibb.
5